Alltrna

Alltrna, a Flagship Pioneering company, is unlocking the therapeutic potential of transfer RNA (tRNA) to create a new paradigm in genetic medicine. Its platform aims to treat thousands of diseases with a single, universal tRNA medicine by correcting shared premature termination codon (PTC) mutations. The company has demonstrated preclinical proof-of-concept for its first development candidate, AP003, and is building a robust pipeline for liver and other stop codon diseases. Backed by significant venture capital, Alltrna is led by an experienced team focused on translating its novel platform into transformative therapies.

A proprietary platform combining machine learning and tRNA biology to engineer programmable tRNA oligonucleotides. It designs, modifies, synthesizes, and delivers chemically modified tRNAs to restore protein production disrupted by genetic mutations, starting with premature termination codon (PTC) readthrough.

Alltrna competes with small molecule readthrough agents (e.g., PTC Therapeutics) and disease-specific gene therapies/editing approaches. Its differentiation lies in the potential for codon-specific precision, a platform for broad applicability across diseases sharing a mutation, and the programmability of its tRNA molecules, offering a potentially best-in-class profile for nonsense mutations.